31 results
424B5
LUMO
Lumos Pharma Inc
30 Dec 20
Prospectus supplement for primary offering
4:36pm
, 2020;
our revised definitive proxy statement on Schedule 14A filed February 13, 2020 in connection with the Company’s special meeting of stockholders … ;
the supplement to our proxy statement on Schedule 14A filed March 6, 2020 in connection with the Company's special meeting of stockholders;
our
424B3
LUMO
Lumos Pharma Inc
10 Aug 20
Prospectus supplement
7:03am
, 2020 in connection with the Company’s special meeting of stockholders;
the supplement to our proxy statement on Schedule 14A filed March 6, 2020 … in connection with the Company's special meeting of stockholders;
our Current Reports on Form 8-K filed with the SEC on March 18, 2020, March 27, 2020
8-K/A
EX-99.2
ihbytjh5yr3w2q990k
1 Jun 20
Other Events
12:00am
8-K
hyg0u8 kyt0v
18 Mar 20
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
4:37pm
DEFA14A
38l4rjj24n
6 Mar 20
Additional proxy soliciting materials
8:14am
DEFA14A
zogu7wd gwt5
28 Feb 20
Additional proxy soliciting materials
9:10am
8-K
EX-99.1
d0mn05pcunlbgt 83d
28 Feb 20
NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
9:08am
DEFR14A
r4ki46cja 1ncu5
13 Feb 20
Revised proxy
4:37pm
DEFM14A
xbip9l0k
10 Feb 20
Proxy related to merger
8:30am
PRER14A
l8dpai ju
9 Jan 20
Preliminary revised proxy
8:02am
DFAN14A
vvoete5t8ld9whavu3
13 Dec 19
Additional proxy materials by non-management
9:11am
PREM14A
ubel3ogx7erl12
20 Nov 19
Preliminary proxy related to merger
6:38am